Stichworte
Alzheimer-Krankheit ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

182 Suchergebnisse.

Eligibility Mild Cognitive Impairment NCT02353884

- 17.01.19 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Multi-modality MRI Study on Prediction for Mild Cognitive Impairment Conversion; ODM derived from: https://clinicaltrials.gov/show/NCT02353884

Eligibility Behavioral and Psychological Symptoms in Alzheimer's Disease NCT02103673

- 06.12.18 - 1 Formular, 2 Itemgruppen, 8 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia; ODM derived from: https://clinicaltrials.gov/show/NCT02103673

Eligibility Memory Disorders NCT00938665

- 26.09.18 - 1 Formular, 4 Itemgruppen, 33 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria AD Cohort, Inclusion criteria normal control, Exclusion Criteria AD Cohort, Exclusion criteria normal control
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.; ODM derived from: https://clinicaltrials.gov/show/NCT00938665

Eligibility Memory Complaint NCT02062099

- 24.09.18 - 1 Formular, 4 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Common inclusion Criteria, Inclusion criteria for mild to moderate Alzheimer's, Inclusion criteria for amnestic mci patients, Inclusion criteria for patients with isolated memory complaint
PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO); ODM derived from: https://clinicaltrials.gov/show/NCT02062099

Eligibility Moderate to Severe Alzheimer's Disease NCT00866060

- 24.06.18 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Donepezil and Memantine in Moderate to Severe Alzheimer's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00866060

Eligibility Mild Alzheimer's Disease NCT01013610

- 22.06.18 - 1 Formular, 2 Itemgruppen, 16 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT01013610

Eligibility Dementia, Alzheimer Type NCT00997425

- 06.02.18 - 1 Formular, 2 Itemgruppen, 14 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Home Evaluation of Exit Barriers in Wandering; ODM derived from: https://clinicaltrials.gov/show/NCT00997425

Eligibility Caregivers NCT00558402

- 28.11.17 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Meditation or Education for Alzheimer Caregivers; ODM derived from: https://clinicaltrials.gov/show/NCT00558402

GSK AVA100193 Rosiglitazone in Alzheimer´s Disease - Study Conclusion - Study Conclusion

- 25.09.17 - 1 Formular, 1 Itemgruppe, 16 Datenelemente, 1 Sprache
Itemgruppe: Study Conclusion
A 24 week double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease.

GSK AVA100193 Rosiglitazone in Alzheimer´s Disease - Pharmacogenetic and Pharmacogenomic Research - Pharmacogenetic and Pharmacogenomic Research

- 25.09.17 - 1 Formular, 1 Itemgruppe, 10 Datenelemente, 1 Sprache
Itemgruppe: PGx-Pharmacogenetic/PGm-Transcriptomic/PGM-Proteomic Research
A 24 week double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease.

GSK AVA100193 Rosiglitazone in Alzheimer´s Disease - Running Logs - Running Logs

- 25.09.17 - 1 Formular, 1 Itemgruppe, 69 Datenelemente, 1 Sprache
Itemgruppe: Running Logs
A 24 week double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease.

Visit 6-8 plus Follow-up

- 25.09.17 - 1 Formular, 4 Itemgruppen, 122 Datenelemente, 1 Sprache
Itemgruppen: Visit 6, Visit 7, Visit 8, Study End Follow-up
A 24 week double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease.